English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Severe Acute Respiratory Syndrome (SARS) is an acute respiratory illness caused by infection with a novel coronavirus (SARS-CoV). Infection by SARS coronaviruses requires fusion of the viral and cellular membranes, which is mediated by the viral envelope Spike (S) glycoprotein and receptors on the target cell. The S protein contains two hydrophobic repeat regions, denoted HRN and HRC, which oligomerize the S glycoprotein into a trimer in the native state, and when activated collapse into a six-helix bundle structure driving fusion of the host and viral membranes. We and others have previously reported that the HR regions of SARSCoV S protein can associate to form a very stable helical six-stranded structure and residues 902–950 in HRN and 1151–1185 in HRC were identified to be crucial for their interaction [1-4]. Due to the severity and mortality (10%) witnessed in the fall of 2003 during the spread of the SARS-CoV pandemic, and the current lack of effective agents for the antiviral therapy of SARS-CoV infection, it has become imperative to learn as much as possible about this virus and the ability to prevent future infection. As successfully used in fusion inhibitor design for HIV [5], peptides derived from HRC can bind to the transiently exposed HRN coiled-coil trimer and block the formation of the six-helical bundle (Fig. 1), which ultimately leads to a loss of membrane-fusion activity. In this study, HRN (902-950) peptide of SARS-CoV S protein was chosen as the target for testing the interaction of HRC analogs. The 36-residue HRC peptide (1150-1185) was chosen as the region to design a series of HRC analogs, in order to increase their stability and binding affinity with HRN. These substitutions /modifications involved: (1) increasing helical propensity (HRC2 and HRC4); (2) increasing hydrophobicity in the hydrophobic core (HRC1 and HRC3); and (3) introducing a lactam bridge (HRC5). The sequences of these peptides are shown in Figure 2.

Design and Study of Novel Peptide Inhibitors against the SARS-Coronavirus Spike Protein